|Bid||135.05 x 800|
|Ask||135.70 x 1300|
|Day's Range||132.44 - 136.50|
|52 Week Range||96.42 - 164.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||169.00|
Let's check out the Yahoo Finance charts of the day. Party City (PRTY): Shares are up in early trade, at around 4.6%. The party goods retailer with sell products on Amazon.com in a pilot program beginning with this year's Halloween season. The company also reported adjusted quarterly profit of 40 cents per share, 1 cent a share above estimates. Roku (ROKU): Shares are up here, at around 18.50%. The streaming video company reported a breakeven quarter, better than the 15 cents per share loss that analysts anticipated. The company also saw revenue and the number of active accounts beat Street forecasts. GW Pharma (GWPH): Shares up here, at around .77%. The drugmaker set a price of $32,500 per year for its new epilepsy treatment, the first cannabis-based prescription drug to be approved by the Food and Drug Administration For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. According to Matteis, Epidiolex is such a potential money maker that GW’s story will come down to execution and access. Matteis expects a strong launch for Epidiolex, he predicted an 80 percent chance of success for the drug in Tuberous Sclerosis complex and he said extension of GW's intellectual property over time could all drive upside in the stock.
GW Pharmaceuticals (NASDAQ: GWPH), a British biopharma, recently reported its third quarter earnings and progress on its cannabis-based drug for people suffering from epilepsy. The biopharma company reported an EPS of -$1.26 in fiscal Q3 compared with the Thomson Reuters’ estimate of -$2.40, while its top line touched $3.46 million in the quarter compared with Reuters’ estimates of $2 million. Apart from the financials, the highlight of the call was the update on its flagship cannabis-based epilepsy drug Epidiolex, which received U.S. FDA approval in June and will most likely hit the markets this fall.
Micron, Ultra Clean Holdings, Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties, Molson Coors and Constellation Brands highlighted as Zacks Bull and Bear of the Day
GW Pharmaceuticals PLC said it plans to charge about $32,500 per patient annually in the U.S. for its new treatment for rare forms of epilepsy, the first prescription drug derived from the marijuana plant. The U.S. Food and Drug Administration approved Epidiolex, also known as cannabidiol, in June to reduce seizures associated with forms of epilepsy known as Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older.
The marijuana market offers investors a significant opportunity, but not every marijuana stock will be a smart investment. This is what you should know about this budding market before you invest a dime of your money.
GW Pharmaceuticals NASDAQ:GWPH) stock was flat late in the day Tuesday as the company reported its latest quarterly earnings results, which saw its loss widen year-over-year, while revenue increased. For its first three quarters of fiscal 2018, the pharmaceutical company brought in cash equivalents of £334.0 million ($440.2 million), which was larger than the cash equivalents of £241.2 million that it had as of September 30, 2017. “The recent FDA approval of Epidiolex represents a major medical advance for patients with Lennox-Gastaut Syndrome and Dravet syndrome,” said Justin Gover, GW’s CEO, in relation to one of its most exciting products in the pipeline.
-Epidiolex ® oral solution approved by FDA and on track to be launched in Fall-- Conference call today at 4:30 p.m. ET-. LONDON and CARLSBAD, Calif., Aug. 07, 2018-- GW Pharmaceuticals plc, the world leader ...
As California works out the kinks in its new, if long-anticipated, adult-use market and Canada prepares to roll out its nationwide industry in October, the overall cannabis industry in North America is already a multi-billion-dollar enterprise. A particularly prominent development is the diversity of hemp-based CBD products made from high-CBD, low-THC hemp. As some welcome it as a victory for medical cannabis, it may yet prove to further muddy the question of legality for CBD.
GW Pharma (GWPH) is expected to report its fiscal third-quarter results next week. Investors focus is expected to be on the commercialization plan for Epidiolex.
HENDERSON, NV / ACCESSWIRE / August 3, 2018 / On June 25, the FDA approved London-based GW Pharma's Epidiolex, a drug containing CBD as its active ingredient, to treat two rare and severe forms of epilepsy, ...
Insys continues to suck in investors who think the company is ripe for a good study result or positive nod from the U.S. Food & Drug Administration (FDA) -- and that its cheap. The latest rejection came on Friday when the FDA decided not to approve Insys' drug buprenorphine sublingual spray to treat pain as an alternative to opioids.
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering how cannabinoids are currently being used by physicians and how companies, such as Pascal Biosciences Inc. (PAS.V), are exploring new treatment options and combination therapies. The liberalization of cannabis laws around the world has opened the door for researchers to explore the therapeutic benefits of cannabinoids. Cannabinoids have been primarily used by physicians to treat the side-effects of cancer.
GW Pharmaceuticals plc (GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018 its third quarter financial results for the period ending 30 June, 2018. GW will also host a conference call the same day at 4:30 p.m. EDT. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
CarMax, J.M. Smucker, Innovative Industrial Properties and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day